SIGLECL1

Across TCGA pan-cancer cohorts, SIGLECL1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SIGLECL1 data layer compared with 17 for mass-spec protein.

The strongest signal is observed in rectum adenocarcinoma (READ), where higher SIGLECL1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SIGLECL1 expression acts as an unfavorable survival marker.

READ, UCEC, and SKCM are the cancer types where SIGLECL1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
READ	DFS	Median	All	0.182	0.798	.010	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	OS	Median	IV	0.179	0.755	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SIGLECL1–READ (DFS)

Open the READ breakdown →